Amarin shareholders don't know what to make of ongoing patent issues because management refuses to communicate clearly and openly. No one expects the company to divulge all its competitive secrets, but an honest discussion of the patent-issuing process and timelines would help alleviate uncertainty and fear that is having a huge, negative effect on Amarin's stock price. Sell-side analysts continually defend Amarin, insisting investors are worrying too much about AMR101 patents but it would be better to hear from Amarin management itself. Amarin shareholders deserve better treatment from executives who are supposed to be working in their best interests. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.